Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
FULC Fulcrum Therapeutics
- 3.690
- -0.020-0.54%
Close Feb 14 16:00 ET
- 3.690
- 0.0000.00%
Post 16:01 ET
199.03MMarket Cap-12.72P/E (TTM)
3.940High3.625Low848.39KVolume3.760Open3.710Pre Close3.16MTurnover2.89%Turnover RatioLossP/E (Static)53.94MShares13.70052wk High0.77P/B108.48MFloat Cap2.86052wk Low--Dividend TTM29.40MShs Float33.098Historical High--Div YieldTTM8.49%Amplitude2.250Historical Low3.723Avg Price1Lot Size
About Fulcrum Therapeutics Company
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Company Profile
SymbolFULC
Company NameFulcrum Therapeutics
Listing DateJul 18, 2019
Issue Price16.00
Founded2015
CEOMr. Alex C. Sapir
MarketNASDAQ
Employees76
Fiscal Year Ends12-31
Address26 Landsdowne Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-617-651-8851
Websitehttp://www.fulcrumtx.com
Company Executives
- Name
- Position
- Salary
- Alex C. Sapir
- Director, President and Chief Executive Officer
- 6.99M
- Dr. Patrick Taylor Horn, M.D.,PhD.
- Chief Medical Officer
- --
- Alan A. Musso
- Chief Financial Officer and Treasurer
- 1.88M
- Curtis G. Oltmans
- Chief Legal Officer
- 2.32M
- Gregory Tourangeau
- Vice President, Finance, Controller and Principal Accounting Officer
- --
- Melvin H. Hayes, III
- Executive Vice President, Patient Experience
- 2.19M
- Kate Haviland
- Chairman of the Board
- 157.90K
- Dr. Robert J. Gould, PhD
- Director
- 424.50K
- James A. Geraghty
- Independent Director
- 131.90K
- Rachel King
- Independent Director
- --
- Colin Hill
- Independent Director
- --
- Sonja Banks
- Independent Director
- 121.40K
- Katina Dorton, J.D.,M.B.A.
- Independent Director
- 136.40K
- Dr. Alan Ezekowitz, D.Phil.,MB.Ch.B.
- Independent Director
- 131.40K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.